公开(公告)号：US20170314077A1

公开(公告)日：2017-11-02

申请号：US15525623

申请日：2015-11-13

Applicant: BERGENBIO AS

Inventor： David Robert MICKLEM ,  Monica HELLESOY ,  Linn Hodneland NILSSON

IPC: C12Q1/68 ,  G01N33/50 ,  A61K31/502 ,  G01N33/574 ,  C07K14/47

CPC classification number: C12Q1/6886 ,  A61K31/502 ,  C07K14/4703 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5011 ,  G01N33/5088 ,  G01N33/574 ,  G01N33/57426 ,  G01N33/57484 ,  G01N33/57496 ,  G01N2333/4704 ,  G01N2500/10 ,  G01N2800/52 ,  G01N2800/56

Abstract: The use of Slfn11 as a biomarker for detecting the occurrence of epithlial-to-mesenchymal transition (EMT) in a subject, and the use of Slfn11 modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Slfn11 expression and/or activity.

公开(公告)号：US20170313760A1

公开(公告)日：2017-11-02

申请号：US15638667

申请日：2017-06-30

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  C12Q1/68 ,  A61K45/06 ,  C12N5/0783 ,  C12N9/64 ,  C07K7/02 ,  C07K7/06 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  A61K38/08 ,  G01N33/566 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC.

公开(公告)号：USRE46584E1

公开(公告)日：2017-10-24

申请号：US15006882

申请日：2016-01-26

Applicant: Leidos, Inc.

Inventor： John Dresios ,  Richard Holmes Griffey

IPC: G01N33/53 ,  C07K16/00 ,  A61K47/42 ,  G01N33/567 ,  A61K39/44 ,  C07K16/18 ,  A61K9/127 ,  A61K38/02 ,  G01N33/50 ,  A61K47/48 ,  A61K38/17

CPC classification number: G01N33/6887 ,  A61K9/1271 ,  A61K38/02 ,  A61K38/1777 ,  A61K39/44 ,  A61K47/42 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6847 ,  A61K49/0058 ,  C07K16/18 ,  G01N33/5088 ,  G01N33/567 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4712 ,  G01N2333/78

Abstract: The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.

公开(公告)号：US20170258744A1

公开(公告)日：2017-09-14

申请号：US15405653

申请日：2017-01-13

Applicant: Pellficure Pharmaceuticals, Inc.

Inventor： Per Borgström

IPC: A61K31/122 ,  A61K31/167 ,  A61K31/277 ,  A61K31/4166 ,  A61K31/565 ,  A61K31/56 ,  A61K31/58 ,  A61K31/6615 ,  A61K38/09 ,  A61K45/06 ,  G01N33/50 ,  A61K31/05 ,  A61K31/57

CPC classification number: A61K31/122 ,  A61K31/05 ,  A61K31/167 ,  A61K31/277 ,  A61K31/4166 ,  A61K31/56 ,  A61K31/565 ,  A61K31/57 ,  A61K31/58 ,  A61K31/6615 ,  A61K38/09 ,  A61K45/06 ,  G01N33/5011 ,  G01N33/5088 ,  A61K2300/00

Abstract: Disclosed herein are naphthoquinone analogs, such as plumbagin, pharmaceutical compositions that include naphthoquinone analogs, such as plumbagin, and methods of treating diseases and/or conditions such as cancer with naphthoquinone analogs, such as plumbagin. Also included are combination therapies wherein a naphthoquinone analog, such as plumbagin, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

公开(公告)号：US20170248582A1

公开(公告)日：2017-08-31

申请号：US15521630

申请日：2015-10-29

Applicant: Syntivia ,  Centre Hospitalier Universitaire de Toulouse ,  Universite Paul Sabatier - Toulouse III ,  Centre National de la Recherche Scientifique

Inventor： Marine Norlund ,  Bernard Ducommun ,  Philippe Bedos ,  Valérie Lobjois

IPC: G01N33/50 ,  C12N5/071

CPC classification number: G01N33/5088 ,  C12N5/0626 ,  C12N5/063 ,  C12N5/0698 ,  C12N2533/50 ,  C12N2533/90 ,  G01N33/5023 ,  G01N2500/10

Abstract: The present invention concerns the development of a model to evaluate active substances targeting the epidermis. It more particularly relates to the preparation of mixed spheroids of melanocytes and keratinocytes reproducing cell interactions occurring in the epidermis, to the spheroids as such and to the uses thereof.

公开(公告)号：US09746463B2

公开(公告)日：2017-08-29

申请号：US14032008

申请日：2013-09-19

Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

Inventor： Gerard Karsenty ,  Patricia F. Ducy

IPC: A61K38/16 ,  G01N33/543 ,  A61K38/39 ,  A61K47/48 ,  G01N33/50

CPC classification number: G01N33/54306 ,  A61K38/16 ,  A61K38/39 ,  A61K47/60 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/5023 ,  G01N33/5038 ,  G01N33/5088 ,  G01N2333/78 ,  G01N2333/916 ,  G01N2333/988

Abstract: The present invention relates to methods and compositions for treating and diagnosing disorders related to energy metabolism and the OST-PTP signaling pathway involving gamma-carboxylase, osteocalcin and adiponectin. Such disorders include, but are not limited to, metabolic syndrome, glucose intolerance, diabetes types 1 and 2, atherosclerosis and obesity.

公开(公告)号：US20170199195A1

公开(公告)日：2017-07-13

申请号：US15320847

申请日：2015-06-25

Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.

Inventor： Benjamin DEKEL ,  Orit HARARI-STEINBERG

IPC: G01N33/574 ,  A61K31/275 ,  C12Q1/68

CPC classification number: G01N33/57407 ,  A61K31/275 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/5073 ,  G01N33/5088 ,  G01N33/57484 ,  G01N2333/90203

Abstract: A method of identifying cancer stem cell markers in a human primary tumor is disclosed. The method comprises: (a) in vivo passaging the primary tumor; and (b) comparing a level of at least one antigen in a first population of passaged tumor cells of the primary tumor with a second population of tumor cells of the primary tumor, wherein an increase in the amount of the antigen in the first population of tumor cells as compared to the amount of the antigen in the second population of tumor cells is indicative of a cancer stem cell marker in the human primary tumor.

公开(公告)号：US09702867B2

公开(公告)日：2017-07-11

申请号：US15278933

申请日：2016-09-28

Applicant: BioCrine AB

Inventor： Per-Olof Berggren

IPC: A61K49/00 ,  G01N33/50 ,  A61B3/10 ,  A61B5/00 ,  A61B3/13

CPC classification number: G01N33/5026 ,  A61B3/10 ,  A61B3/13 ,  A61B5/0068 ,  A61B5/0071 ,  A61B5/4227 ,  A61B5/425 ,  A61B5/4842 ,  A61B5/4848 ,  A61K49/0004 ,  A61K49/0008 ,  A61K49/0041 ,  A61K49/0054 ,  A61K49/0097 ,  G01N33/5088 ,  G01N2800/042

Abstract: The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.

公开(公告)号：US20170164588A1

公开(公告)日：2017-06-15

申请号：US14949834

申请日：2015-11-23

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Kara L. Olson ,  Eric Smith ,  Ka-Man Venus Lai ,  Andrew J. Murphy ,  Gavin Thurston ,  Dayong Guo

IPC: A01K67/027 ,  C07K14/725

CPC classification number: A01K67/0278 ,  A01K67/0276 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  A01K2267/0337 ,  C07K14/7051 ,  G01N33/5088 ,  Y02A50/57

Abstract: Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.

公开(公告)号：US09670260B2

公开(公告)日：2017-06-06

申请号：US14983280

申请日：2015-12-29

Applicant: NGM Biopharmaceuticals, Inc.

Inventor： Lei Ling ,  Darrin Anthony Lindhout

IPC: A61K38/18 ,  C07K14/50 ,  C12N1/21 ,  C12N5/10 ,  C12N15/63 ,  G01N33/50 ,  A61K31/14 ,  A61K31/155 ,  A61K45/06 ,  A61K31/785 ,  A61K38/00

CPC classification number: C07K14/50 ,  A61K31/14 ,  A61K31/155 ,  A61K31/785 ,  A61K38/00 ,  A61K38/1825 ,  A61K45/06 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/5088 ,  G01N33/66

Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.